Cargando…
CNS penetration of potential anti-COVID-19 drugs
Autores principales: | Richardson, Peter J., Ottaviani, Silvia, Prelle, Alessandro, Stebbing, Justin, Casalini, Giacomo, Corbellino, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195609/ https://www.ncbi.nlm.nih.gov/pubmed/32361836 http://dx.doi.org/10.1007/s00415-020-09866-5 |
Ejemplares similares
-
Baricitinib for COVID-19: a suitable treatment? – Authors' reply
por: Richardson, Peter J, et al.
Publicado: (2020) -
Longitudinal assessment of systemic steroid therapy on hyperinflammatory endothelial biomarker profiles and serology responses of COVID-19 patients
por: Sims, Jonathan T., et al.
Publicado: (2022) -
What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials
por: Ottaviani, Silvia, et al.
Publicado: (2020) -
Why need for five anti-tubercular drugs in a child with CNS TB?
por: Bagalkot, Praveen S.
Publicado: (2012) -
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
por: Cattaneo, Dario, et al.
Publicado: (2020)